Online GLP-1 Programs in Montana

Insurance

Does Montana Medicaid cover GLP-1s?

Montana Medicaid does not cover GLP-1s for weight loss; a 2025 coverage bill (SB 417) did not advance (RX Index, 2026). Montana expanded Medicaid, but obesity drug coverage is optional and the state has not adopted it. GLP-1s for type 2 diabetes are covered, as federal law requires.

Online Access

Getting a GLP-1 online in Montana

GLP-1s are not controlled substances, so Montana allows them to be prescribed via telehealth when a Montana-licensed clinician meets the standard of care. Telehealth is a meaningful access channel given Montana's frontier geography and long distances to in-person care.

Compounding

Compounded semaglutide & tirzepatide in Montana

Routine compounding of semaglutide and tirzepatide ended after the FDA resolved the shortages in early 2025 (FDA, 2025). Montana adds no special carve-out beyond the federal 503A/503B framework, so compounding is limited to documented, patient-specific clinical need.

Demand

Where GLP-1 demand is highest in Montana

About 31% of Montana adults have obesity and roughly 9% have diagnosed diabetes, one of the lowest diabetes rates in the country (CDC BRFSS via America's Health Rankings, 2024). Demand centers on Billings, Missoula, and fast-growing Bozeman. With most of its 56 counties designated primary-care shortage areas, Montana relies heavily on telehealth, which is also the main route for weight-loss GLP-1s that Medicaid does not cover.

Online GLP-1 near you in Montana

GLP-1 care here is delivered by telehealth, so you do not need a weight-loss clinic in Billings or Missoula specifically. Residents across Montana, including Billings, Missoula, Great Falls, Bozeman, Butte, can compare online semaglutide and tirzepatide programs and confirm eligibility and pricing during a short intake, with no in-person visit required.

Affiliate link. Sponsored.

Questions

Montana GLP-1 FAQ

Compound Guides

The GLP-1s behind these programs

Sources

How we sourced this page

Coverage, prevalence, and policy figures are drawn from primary and authoritative sources, last reviewed June 2026.